TIMP3 Cancer Research Results
TIMP3, tissue inhibitor of metalloproteinases-3: Click to Expand ⟱
| Source: |
| Type: |
TIMP-3 has been shown to have tumor suppressor properties, as it inhibits the activity of MMPs, which are involved in tumor growth, invasion, and metastasis.
|
Scientific Papers found: Click to Expand⟱
AntiCan↑, Carvacrol has demonstrated strong anticancer properties by modulating multiple molecular pathways governing apoptosis, inflammation, angiogenesis, and metastasis.
Apoptosis↑,
Inflam↓,
angioG↓,
TumMeta↓,
selectivity↑, revealed its ability to selectively target cancer cells while sparing healthy tissue
BioAv↑, nanotechnology have further enhanced its pharmacological profile by improving solubility, stability, and tumor-targeted delivery.
ChemoSen↑, synergistic effects when used in combination with conventional chemotherapeutics.
Dose↝, 84.38% of OEO’s contents are ‘carvacrol’.
TumCP↓, limit metastasis, induce apoptosis, suppress tumor cell proliferation, and improve the effectiveness of traditional chemotherapy medications
hepatoP↑, Carvacrol shows biological activities, such as antimicrobial, antitumor, antimutagenic, antigenotoxic, anti-inflammatory, anti-angiogenic, hepatoprotective, and antihepatotoxic properties.
Casp3↑, induced apoptosis by activating caspase-3 and caspase-9 while downregulating Bcl-2 mRNA levels
Casp9↑,
Bcl-2↓,
ROS↑, carvacrol causes oxidative stress by increasing the production of reactive oxygen species (ROS) and depleting GSH levels, which results in strong lethal effects on AGS gastric cancer
GSH↓,
BAX↑, upregulating pro-apoptotic markers such as Bax, caspase-3, caspase-7, caspase-8, caspase-9, cytochrome C, Fas, Fas-associated death domain (FADD), and p53
Casp7↑,
Casp8↑,
Cyt‑c↑,
Fas↑,
FADD↑,
P53↑,
Bcl-2↓, downregulating anti-apoptotic Bcl-2.
TumMeta↓, preventing metastasis by limiting the migration and invasion of cancer cells by upregulating epithelial markers like E-Cadherin and tissue inhibitors of metalloproteinases 2 and 3 (TIMP2 and TIMP3)
TumCMig↓,
TumCI↓,
E-cadherin↑,
TIMP2↑,
TIMP3↑,
N-cadherin↓, downregulating mesenchymal markers like N-Cadherin and ZEB2
ZEB2↓,
*lipid-P↓, protects the liver from diethylnitrosamine (DEN)-induced hepatocellular carcinogenesis by reducing lipid peroxidation, restoring key liver enzymes (AST, ALT, ALP, LDH, cGT)
*AST↓,
*ALAT↓,
*ALP↓,
*LDH↓,
*SOD↑, and enhancing antioxidant defenses (SOD, CAT, GPx, GR, GSH)
*Catalase↑,
*GPx↑,
*GSR↑,
selectivity↑, while selectively inducing apoptosis in cancer cells without harming normal liver tissue
cl‑PARP↑, inhibits HepG2 cancer cell growth by activating caspase-3, promoting PARP cleavage, downregulating Bcl-2, and modulating the MAPK signaling pathway by selectively reducing ERK1/2 phosphorylation while activating p38
ERK↓,
p38↑,
OS↑, rats (aged 6–8 weeks) demonstrated that carvacrol enhances sorafenib efficacy in HCC, improving survival rates, reducing tumor progression, and mitigating sorafenib-induced cardiac and hepatic toxicity.
AFP↓, carvacrol reduces serum alpha-fetoprotein (AFP) and alpha-L-fucosidase (AFU) levels by downregulating COX-2 and oxidative stress, inhibits angiogenesis via VEGF suppression,
COX2↓,
VEGF↓,
PCNA↓, prevents tumor proliferation by downregulating proliferating cell nuclear antigen (PCNA) and Ki-67 through TNF-α suppression.
Ki-67↓,
TNF-α↓,
BioAv↓, Despite carvacrol’s promising effects in vitro and in vivo, limitations such as bioavailability and solubility challenge its therapeutic application.
TIMP3↑,
MMP2↓,
MMP9↓,
DNMTs↓, When nuclear extracts were incubated with increasing doses of quercetin (25 and 50uM) they were found to inhibit the function of the DNMTs by 32% and 49% respectively, in comparison to untreated control
HDAC↓, quercetin (25 and 50 uM), they were found to inhibit the function of the HDACs by 47% and
62% in comparison to untreated control.
HMTs↓, quercetin (25 and 50 uM), were found to inhibit the function of the HMT H3K9 by 63%
and 71%
DNMT3A↓, preferred binding of quercetin on DNMT3A and DNMT3B is within the substrate binding cavity and could competitively inhibit the protein
EZH2↓, Quercetin interacts with EZH2 and functions as an inhibitor
HDAC1↓, Quercetin was able to reduce the activity of class II HDACs significantly, with concomitant downregulation of HDAC1, HDAC2, HDAC6, HDAC7, and HDAC11 expression
HDAC2↓,
HDAC6↓,
HDAC11↓,
G9a↓, quercetin and this correlates well with the observed downregulation of G9A expression
TIMP3↑, Fig8: quercetin resulted in reduced promoter methylation of several TSGs (APC, CDH1, CDH13, DAPK1, FHIT, GSTP1, MGMT, MLH1, PTEN, RARB, RASSF1, SOC51, TIMP3, and VHL
PTEN↑,
SOCS1↑,
| - |
in-vitro, |
Pca, |
LNCaP |
|
|
|
- |
in-vitro, |
Pca, |
PC3 |
|
|
|
- |
in-vitro, |
Pca, |
DU145 |
|
|
|
TET1↑, Res upregulated the 5hmC and TET1 levels and downregulated the 5mC level.
TumCMig↓, Res also inhibited the migration and invasion of PCa cells
TumCI↓,
TIMP2↑, promoted the demethylation of TIMP2 and TIMP3 to upregulate their expressions, and suppressed the expressions of MMP2 and MMP9.
TIMP3↑,
MMP2↓,
MMP9↓,
Showing Research Papers: 1 to 4 of 4
* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 4
Pathway results for Effect on Cancer / Diseased Cells:
Redox & Oxidative Stress ⓘ
GSH↓, 1, ROS↑, 1,
Cell Death ⓘ
Apoptosis↑, 1, BAX↑, 1, Bcl-2↓, 2, Casp3↑, 1, Casp7↑, 1, Casp8↑, 1, Casp9↑, 1, Cyt‑c↑, 1, FADD↑, 1, Fas↑, 1, p38↑, 1,
Transcription & Epigenetics ⓘ
EZH2↓, 1,
DNA Damage & Repair ⓘ
DNMT3A↓, 1, DNMTs↓, 1, G9a↓, 1, P53↑, 1, cl‑PARP↑, 1, PCNA↓, 1,
Proliferation, Differentiation & Cell State ⓘ
ERK↓, 1, HDAC↓, 1, HDAC1↓, 1, HDAC11↓, 1, HDAC2↓, 1, HDAC6↓, 1, HMTs↓, 1, PTEN↑, 1,
Migration ⓘ
E-cadherin↑, 1, Ki-67↓, 1, MMP2↓, 2, MMP9↓, 2, N-cadherin↓, 1, TET1↑, 1, TIMP2↑, 2, TIMP3↑, 4, TumCI↓, 2, TumCMig↓, 2, TumCP↓, 1, TumMeta↓, 2, ZEB2↓, 1,
Angiogenesis & Vasculature ⓘ
angioG↓, 1, VEGF↓, 1,
Immune & Inflammatory Signaling ⓘ
COX2↓, 1, Inflam↓, 1, SOCS1↑, 1, TNF-α↓, 1,
Drug Metabolism & Resistance ⓘ
BioAv↓, 1, BioAv↑, 1, ChemoSen↑, 1, Dose↝, 1, selectivity↑, 2,
Clinical Biomarkers ⓘ
AFP↓, 1, EZH2↓, 1, Ki-67↓, 1,
Functional Outcomes ⓘ
AntiCan↑, 1, hepatoP↑, 1, OS↑, 1,
Total Targets: 58
Pathway results for Effect on Normal Cells:
Redox & Oxidative Stress ⓘ
Catalase↑, 1, GPx↑, 1, GSR↑, 1, lipid-P↓, 1, SOD↑, 1,
Core Metabolism/Glycolysis ⓘ
ALAT↓, 1, LDH↓, 1,
Clinical Biomarkers ⓘ
ALAT↓, 1, ALP↓, 1, AST↓, 1, LDH↓, 1,
Total Targets: 11
Scientific Paper Hit Count for: TIMP3, tissue inhibitor of metalloproteinases-3
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include :
-low or high Dose
-format for product, such as nano of lipid formations
-different cell line effects
-synergies with other products
-if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:823 State#:% Dir#:2
wNotes=on sortOrder:rid,rpid
Home Page